Skip to main content
Top
Published in: AIDS and Behavior 3/2014

01-03-2014 | Brief Report

Social Network Structure and HIV Infection Among Injecting Drug Users in Lithuania: Gatekeepers as Bridges of Infection

Authors: V. Anna Gyarmathy, Irma Caplinskiene, Saulius Caplinskas, Carl A. Latkin

Published in: AIDS and Behavior | Issue 3/2014

Login to get access

Abstract

The aim of the study was to assess—while controlling for individual risk characteristics—how certain social network structural characteristics (degree, eigenvector, and betweenness centrality) are related to HIV infections. Injecting drug users (N = 299) in Vilnius, Lithuania were recruited using incentivized chain referral sampling for a cross-sectional study. Sociometric social links were established between participants, and UCINET was used to calculate network measures. HIV prevalence was 10 %, and all except two knew they were infected. Of the five variables that remained significant in the final multivariate model, one showed temporal cumulative infection risk (more years since first drug injecting), three reflected informed altruism (always using condoms, less distributive syringe sharing and having not more than one sex partner), and one pointed to the importance of social network structure (betweenness centrality, indicating bridge populations). Loess regression indicates that betweenness may have the highest impact on HIV prevalence (about 60 vs. 20 % estimated HIV prevalence for the highest betweenness centrality values vs. highest age values). This analysis contributes to existing evidence showing both potential informed altruism (or maybe social desirability bias) in connection with HIV infection, and a link between HIV infection risk and the role of bridges within the social network of injecting drug user populations. These findings suggest the importance of harm reduction activities, including confidential testing and counseling, and of social network interventions.
Literature
1.
go back to reference Pilon R, Leonard L, Kim J, et al. Transmission patterns of HIV and hepatitis C virus among networks of people who inject drugs. PLoS One. 2011;6:e22245.PubMedCentralPubMedCrossRef Pilon R, Leonard L, Kim J, et al. Transmission patterns of HIV and hepatitis C virus among networks of people who inject drugs. PLoS One. 2011;6:e22245.PubMedCentralPubMedCrossRef
2.
go back to reference Adimora AA, Schoenbach VJ, Doherty IA. HIV and African Americans in the southern United States: sexual networks and social context. Sex Transm Dis. 2006;33:S39–45.PubMedCrossRef Adimora AA, Schoenbach VJ, Doherty IA. HIV and African Americans in the southern United States: sexual networks and social context. Sex Transm Dis. 2006;33:S39–45.PubMedCrossRef
3.
go back to reference Howard DL, Latkin CA. A bridge over troubled waters: factors associated with non-injection drug users having injection drug-using sex partners. J Acquir Immune Defic Syndr. 2006;42:325–30.PubMedCrossRef Howard DL, Latkin CA. A bridge over troubled waters: factors associated with non-injection drug users having injection drug-using sex partners. J Acquir Immune Defic Syndr. 2006;42:325–30.PubMedCrossRef
4.
go back to reference Young AM, Jonas AB, Mullins UL, Halgin DS, Havens JR. Network structure and the risk for HIV transmission among rural drug users. AIDS Behav. 2013;17(7):2341–51.PubMedCrossRef Young AM, Jonas AB, Mullins UL, Halgin DS, Havens JR. Network structure and the risk for HIV transmission among rural drug users. AIDS Behav. 2013;17(7):2341–51.PubMedCrossRef
6.
go back to reference Hanneman RA, Riddle M. Introduction to social network methods. Riverside: University of California, Riverside; 2005. Hanneman RA, Riddle M. Introduction to social network methods. Riverside: University of California, Riverside; 2005.
7.
go back to reference Gyarmathy VA, Neaigus A, Li N, et al. Liquid drugs and high dead space syringes may keep HIV and HCV prevalence high - a comparison of Hungary and Lithuania. Eur Addict Res. 2010;16:220–8.PubMedCentralPubMedCrossRef Gyarmathy VA, Neaigus A, Li N, et al. Liquid drugs and high dead space syringes may keep HIV and HCV prevalence high - a comparison of Hungary and Lithuania. Eur Addict Res. 2010;16:220–8.PubMedCentralPubMedCrossRef
8.
go back to reference Gyarmathy VA, Neaigus A. The effect of personal network exposure on injecting equipment sharing among Hungarian IDUs. Connections. 2006;15:29–42. Gyarmathy VA, Neaigus A. The effect of personal network exposure on injecting equipment sharing among Hungarian IDUs. Connections. 2006;15:29–42.
9.
go back to reference Borgatti SP, Everett MG, Freeman LC. Ucinet for Windows: Software for Social Network Analysis. Harvard: Analytic Technologies; 2002. Borgatti SP, Everett MG, Freeman LC. Ucinet for Windows: Software for Social Network Analysis. Harvard: Analytic Technologies; 2002.
10.
go back to reference Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988;83:596–610.CrossRef Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988;83:596–610.CrossRef
12.
go back to reference Neaigus A. Gyarmathy VA, Zhao M, Miller M, Friedman SR, and Des Jarlais DC. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis. 2007;195:1052–61.PubMedCrossRef Neaigus A. Gyarmathy VA, Zhao M, Miller M, Friedman SR, and Des Jarlais DC. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis. 2007;195:1052–61.PubMedCrossRef
13.
go back to reference de Vos AS, van der Helm JJ, Matser A, Prins M, Kretzschmar ME. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction. 2013;108(6):1070–81.PubMedCrossRef de Vos AS, van der Helm JJ, Matser A, Prins M, Kretzschmar ME. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction. 2013;108(6):1070–81.PubMedCrossRef
14.
go back to reference Rhodes T and Hedrich D. Harm reduction: evidence, impacts and challenges. Office for Official Publications of the European Communities, 2010. Rhodes T and Hedrich D. Harm reduction: evidence, impacts and challenges. Office for Official Publications of the European Communities, 2010.
15.
go back to reference Des Jarlais DC, Perlis T, Arasteh K, et al. “Informed altruism” and “partner restriction” in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr. 2004;35:158–66.PubMedCrossRef Des Jarlais DC, Perlis T, Arasteh K, et al. “Informed altruism” and “partner restriction” in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr. 2004;35:158–66.PubMedCrossRef
16.
go back to reference Latkin C, Donnell D, Liu TY, Davey-Rothwell M, Celentano D, Metzger D. The dynamic relationship between social norms and behaviors: the results of an HIV prevention network intervention for injection drug users. Addiction. 2013;108(5):934–43.PubMedCrossRef Latkin C, Donnell D, Liu TY, Davey-Rothwell M, Celentano D, Metzger D. The dynamic relationship between social norms and behaviors: the results of an HIV prevention network intervention for injection drug users. Addiction. 2013;108(5):934–43.PubMedCrossRef
Metadata
Title
Social Network Structure and HIV Infection Among Injecting Drug Users in Lithuania: Gatekeepers as Bridges of Infection
Authors
V. Anna Gyarmathy
Irma Caplinskiene
Saulius Caplinskas
Carl A. Latkin
Publication date
01-03-2014
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0702-6

Other articles of this Issue 3/2014

AIDS and Behavior 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine